Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | FBP1 | P09467 | 3/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28228790 | 0.92 | NOS1 (0.45) | NOS1MAPTHSD17B10SMN1; SMN2GAA | |
| SCHEMBL10701474 | 0.79 | DRD2 (0.47) | — | |
| SCHEMBL17481205 | 0.77 | PDE10A (0.36) | PDE10A | |
| SCHEMBL10699833 | 0.72 | DRD2 (0.46) | — | |
| SCHEMBL25142947 | 0.70 | MAPT (0.57) | NOS1MAPTHSD17B10SMN1; SMN2GAA | |
| SCHEMBL21610914 | 0.70 | MEN1 (0.33) | SMN1; SMN2ALDH1A1PDE10A | |
| SCHEMBL21610924 | 0.70 | ALDH1A1 (0.33) | ALDH1A1PDE10A | |
| SCHEMBL1912506 | 0.69 | NOS1 (0.43) | NOS1MAPTHSD17B10SMN1; SMN2CYP1A2 | |
| SCHEMBL21610915 | 0.68 | MEN1 (0.35) | HSD17B10SMN1; SMN2ALDH1A1PDE10A | |
| SCHEMBL14849792 | 0.67 | GABRA1 (0.46) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141262-A1 | BAX ACTIVATORS AND USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2023-07-27 | — | — | WO | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1515721-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050256117-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2005-11-17 | — | — | US | disclosed |
| EP-1515721-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003105847-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | NOS1 3032/4885MAPT 2935/4885HSD17B10 497/4885 |
| US-20050256117-A1 | Ophthalmic compositions for treating ocular hypertension | KCNN1, KCNN3, KCNN2 | NOS1 305/4885MAPT 1089/4885HSD17B10 2457/4885 |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | NOS1 3032/4885MAPT 2935/4885HSD17B10 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.